Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemoimmunotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Chemoimmunotherapy. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2021-006326-48 Sponsor Protocol Number: CO43810 Start Date*: 2022-09-27
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AN...
    Medical condition: CD20 positive B-Cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084346 B-cell non-Hodgkin's lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001532-11 Sponsor Protocol Number: 01apr2014 Start Date*: 2014-09-11
    Sponsor Name:Ospedale San Raffaele
    Full Title: MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RE...
    Medical condition: Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003260-28 Sponsor Protocol Number: KT-US-473-0133 Start Date*: 2022-07-18
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
    Medical condition: Relapsed and/or Refractory Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004851 10085262 Follicular lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009256-20 Sponsor Protocol Number: OMB110928 Start Date*: 2009-12-23
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) SE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) HU (Completed) PL (Prematurely Ended) DE (Prematurely Ended) AT (Completed) EE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005015-16 Sponsor Protocol Number: BBBD-01 Start Date*: 2017-01-24
    Sponsor Name:Oulu University Hospital
    Full Title: Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma
    Medical condition: Primary centra nervous system lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005186-20 Sponsor Protocol Number: 7965-012 Start Date*: 2012-07-12
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL)
    Medical condition: chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) SE (Completed) FI (Completed) LT (Prematurely Ended) LV (Completed) ES (Completed) HU (Completed) IT (Completed) PL (Prematurely Ended) BE (Prematurely Ended) GR (Completed) EE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004936-36 Sponsor Protocol Number: CLL13 Start Date*: 2016-11-08
    Sponsor Name:University of Cologne
    Full Title: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) ve...
    Medical condition: fit patients with previously untreated CLL without del(17p) or TP53 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) AT (Completed) FI (Completed) BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004555-16 Sponsor Protocol Number: M20-429 Start Date*: 2022-04-25
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
    Medical condition: Relapsed/refractory Burkitt's or Burkitt-like lymphoma/leukemia, Diffuse large B-cell lymphoma , or other aggressive mature (CD20+) B-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10006596 Burkitt's lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002324-36 Sponsor Protocol Number: MK1026-003 Start Date*: 2021-03-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054693 Von Waldenstrom macroglobulinemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003170-60 Sponsor Protocol Number: FIL_FOLL12 Start Date*: 2012-08-21
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular...
    Medical condition: Previously untreated intermediate-high risk according to the FLIPI2 stage II-IV follicular lymphoma requiring therapeutic intervention.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061170 Follicle centre lymphoma, follicular grade I, II, III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001099-75 Sponsor Protocol Number: CCRG13-002 Start Date*: 2015-10-13
    Sponsor Name:Antwerp University Hospital
    Full Title: First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma.
    Medical condition: Treatment-naïve malignant pleural mesothelioma patients (eligible for standard chemotherapy and, in case of resectable disease, surgery)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002980-33 Sponsor Protocol Number: BGB-3111-302 Start Date*: 2017-02-21
    Sponsor Name:BeiGene Ltd. c/o BeiGene USA Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macr...
    Medical condition: Subjects with Waldenström’s Macroglobulinemia (WM) who require therapy according to the consensus panel criteria from the 7th International Workshop on Waldenström’s Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047801 Waldenstrom's macroglobulinaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Completed) ES (Completed) NL (Completed) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002443-28 Sponsor Protocol Number: ACE-CL-311/D8221C00001 Start Date*: 2019-05-08
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga...
    Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001502-11 Sponsor Protocol Number: ML18434 Start Date*: 2005-07-18
    Sponsor Name:Roche Austria GmbH
    Full Title: “CHAIROS” – Early brief intensification by chemoimmunotherapy with FCR followed by FR and Rituximab maintenance in chemonaive patients with B-CLL – A phase II study
    Medical condition: Chronic lymphocytic leukemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001068-31 Sponsor Protocol Number: 2019/2894 Start Date*: 2019-09-24
    Sponsor Name:Gustave Roussy
    Full Title: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic p...
    Medical condition: Very High Risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029261 Neuroblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SI (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) SE (Ongoing) SK (Trial now transitioned) ES (Ongoing) DE (Ongoing) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001468-39 Sponsor Protocol Number: GS-US-313-1090 Start Date*: Information not available in EudraCT
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036714 Primary mediastinal large B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012337-29 Sponsor Protocol Number: IILFLE09 Start Date*: 2009-07-20
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma
    Medical condition: Elderly patients with advanced stage previously untreated follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003392-18 Sponsor Protocol Number: FIL_RENOIR12 Start Date*: 2014-04-17
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituxim...
    Medical condition: Maintenance following R-chemotherapy (Rituximab-Bendamustine) of patients with follicular lymphoma in first or second relapse or progression and not eligible for autologous stem cell transplantatio...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003166-39 Sponsor Protocol Number: ChImDLP-2 Start Date*: 2022-08-08
    Sponsor Name:UAB Froceth
    Full Title: A study of the safety of chemoimmunotherapy with autologous Dendritic Cell Preparations in patients with stage III ovarian cancer
    Medical condition: Stage III of high malignancy Ovarian serous adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 15:11:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA